Article
https://www.pharmacytimes.org/on-demand/scientific-advances-in-als
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
PROs Affirm Zongertinib’s Combination of Strong Response Rates With Low Toxicity